Ruiz de Porras, VicençBystrup, SaraMartínez Cardús, AnnaPluvinet Ortega, RaquelSumoy, LauroHowells, LynneJames, Mark I.Iwuji, ChinenyeManzano, José LuisLayos, LauraBugés, CristinaAbad, AlbertMartínez Balibrea, Eva2018-12-102018-12-102016-04-19https://hdl.handle.net/2445/126854Resistance to oxaliplatin (OXA) is a complex process affecting the outcomes of metastatic colorectal cancer (CRC) patients treated with this drug. De-regulation of the NF-kappa B signalling pathway has been proposed as an important mechanism involved in this phenomenon. Here, we show that NF-kappa B was hyperactivated in in vitro models of OXA-acquired resistance but was attenuated by the addition of Curcumin, a non-toxic NF-kappa B inhibitor. The concomitant combination of Curcumin + OXA was more effective and synergistic in cell lines with acquired resistance to OXA, leading to the reversion of their resistant phenotype, through the inhibition of the NF-kappa B signalling cascade. Transcriptomic profiling revealed the up-regulation of three NF-kappa B-regulated CXC-chemokines, CXCL8, CXCL1 and CXCL2, in the resistant cells that were more efficiently down-regulated after OXA + Curcumin treatment as compared to the sensitive cells. Moreover, CXCL8 and CXCL1 gene silencing made resistant cells more sensitive to OXA through the inhibition of the Akt/NF-kappa B pathway. High expression of CXCL1 in FFPE samples from explant cultures of CRC patients-derived liver metastases was associated with response to OXA + Curcumin. In conclusion, we suggest that combination of OXA + Curcumin could be an effective treatment, for which CXCL1 could be used as a predictive marker, in CRC patients.17 p.application/pdfengcc by (c) Ruiz de Porras et al., 2016http://creativecommons.org/licenses/by/3.0/es/Càncer colorectalMedicaments antineoplàsticsCancer colorectalAntineoplastic agentsinfo:eu-repo/semantics/article2018-07-25info:eu-repo/semantics/openAccess27091625